Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
Mult Scler Relat Disord
; 40: 101973, 2020 May.
Article
en En
| MEDLINE
| ID: mdl-32028116
ABSTRACT
BACKGROUND:
Alemtuzumab is a monoclonal antibody targeting CD-52, used for treating relapsing-remitting multiple sclerosis (RRMS).METHODS:
We present a case of a 44-year-old male with RRMS who was admitted due to fever and jaundice after starting treatment with alemtuzumab 12 months ago.RESULTS:
He was diagnosed with hemophagocytic syndrome (HS). Liver biopsy revealed images of hemophagocytosis in Kupffer cells of lobular sinusoid. Management consisted of treatment with corticosteroids.CONCLUSION:
HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple Recurrente-Remitente
/
Linfohistiocitosis Hemofagocítica
/
Alemtuzumab
/
Factores Inmunológicos
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Mult Scler Relat Disord
Año:
2020
Tipo del documento:
Article
País de afiliación:
España